Square Pharmaceuticals (DHA:SQURPHARMA) 3-Year EBITDA Growth Rate : 7.20% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals 3-Year EBITDA Growth Rate?

Square Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was BDT8.01.

During the past 12 months, Square Pharmaceuticals's average EBITDA Per Share Growth Rate was 10.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 7.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Square Pharmaceuticals was 27.50% per year. The lowest was -47.20% per year. And the median was 13.30% per year.

Competitive Comparison of Square Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Square Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Square Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Square Pharmaceuticals (DHA:SQURPHARMA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Square Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Square Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212

Website

https://www.squarepharma.com.bd

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.

Square Pharmaceuticals Headlines

No Headlines